These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37450279)

  • 1. Reply letter to "Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal".
    Hadigal S; Colombo L; Cook J
    J Med Econ; 2023; 26(1):933-934. PubMed ID: 37450279
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal.
    Alvarez FP; Chevalier P; Borms M; Bricout H; Marques C; Soininen A; Sainio T; Petit C; de Courville C
    J Med Econ; 2023; 26(1):710-719. PubMed ID: 36960689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine in the elderly Belgian population.
    Marbaix S; Dauby N; Mould-Quevedo J
    Expert Rev Vaccines; 2023; 22(1):608-619. PubMed ID: 37368472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply letter to "Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial".
    Hadigal S; Colombo L; Haughie S
    Hum Vaccin Immunother; 2022 Nov; 18(5):2085470. PubMed ID: 35674507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population].
    Chen C; Liu GE; Wang MJ; Gao TF; Jia HP; Yang H; Feng LZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):993-999. PubMed ID: 31607044
    [No Abstract]   [Full Text] [Related]  

  • 6. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland.
    Nagy L; Heikkinen T; Sackeyfio A; Pitman R
    Pharmacoeconomics; 2016 Sep; 34(9):939-51. PubMed ID: 27423657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China.
    Jiang M; Li P; Wang W; Zhao M; Atif N; Zhu S; Fang Y
    Vaccine; 2020 Jan; 38(5):1057-1064. PubMed ID: 31787414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population.
    Fochesato A; Sottile S; Pugliese A; Márquez-Peláez S; Toro-Diaz H; Gani R; Alvarez P; Ruiz-Aragón J
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment.
    Calabrò GE; Boccalini S; Panatto D; Rizzo C; Di Pietro ML; Abreha FM; Ajelli M; Amicizia D; Bechini A; Giacchetta I; Lai PL; Merler S; Primieri C; Trentini F; Violi S; Bonanni P; de Waure C
    Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
    Annemans L; Rémy V; Oyee J; Largeron N
    Pharmacoeconomics; 2009; 27(3):231-45. PubMed ID: 19354343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season.
    Salamanca de la Cueva I; Cinconze E; Eckermann T; Nwoji U; Godderis L; Lu E; Martínez-Gómez X; Wang H; Yanni E
    Drug Saf; 2021 Dec; 44(12):1375-1390. PubMed ID: 34694589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysis.
    Minozzi S; Lytras T; Gianola S; Gonzalez-Lorenzo M; Castellini G; Galli C; Cereda D; Bonovas S; Pariani E; Moja L
    EClinicalMedicine; 2022 Apr; 46():101331. PubMed ID: 35360146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis.
    Sandmann FG; van Leeuwen E; Bernard-Stoecklin S; Casado I; Castilla J; Domegan L; Gherasim A; Hooiveld M; Kislaya I; Larrauri A; Levy-Bruhl D; Machado A; Marques DFP; Martínez-Baz I; Mazagatos C; McMenamin J; Meijer A; Murray JLK; Nunes B; O'Donnell J; Reynolds A; Thorrington D; Pebody R; Baguelin M
    Vaccine; 2022 Feb; 40(9):1306-1315. PubMed ID: 35109968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness and Health Impacts of Different Influenza Vaccination Strategies for Children in China.
    Gong Y; Yao X; Peng J; Ma Y; Fang Y; Yan K; Jiang M
    Am J Prev Med; 2023 Jul; 65(1):155-164. PubMed ID: 37037733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain.
    Ruiz-Aragón J; Márquez-Peláez S
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reply letter to "Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018-2019 and 2019-2020 calculated using a retrospective test-negative design".
    Hadigal S; Colombo L; Haughie S
    Hum Vaccin Immunother; 2023 Aug; 19(2):2227034. PubMed ID: 37344371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of randomizing Danish citizens aged 65-79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial.
    Johansen ND; Modin D; Nealon J; Samson S; Salamand C; Larsen CS; Claggett BL; Solomon SD; Landray MJ; Gislason GH; Køber L; Jensen JUS; Sivapalan P; Vestergaard LS; Valentiner-Branth P; Krause TG; Biering-Sørensen T
    Pilot Feasibility Stud; 2022 Apr; 8(1):87. PubMed ID: 35449028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults.
    Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Zimmerman RK
    J Am Geriatr Soc; 2016 Oct; 64(10):2126-2131. PubMed ID: 27709600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany.
    Kohli MA; Maschio M; Cartier S; Mould-Quevedo J; Fricke FU
    Vaccines (Basel); 2022 Aug; 10(9):. PubMed ID: 36146464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the influenza season 2021/22.
    Gandhi-Banga S; Wague S; Shrestha A; Syrkina O; Talanova O; Nissilä M; Stuff K; Monfredo C
    Influenza Other Respir Viruses; 2023 Jan; 17(1):e13071. PubMed ID: 36448240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.